Catabasis Pharmaceuticals, Inc

(NASDAQ:CATB)

Latest On Catabasis Pharmaceuticals, Inc (CATB):

Date/Time Type Description Signal Details
2021-08-10 00:51 ESTNewsCatabasis Pharmaceuticals EPS misses by $0.59N/A
2021-07-20 23:44 ESTNewsCATB, XELB, CLSD and DTEA among after-hours moversN/A
2021-07-20 23:43 ESTNewsCatabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA CapitalN/A
2021-07-20 23:32 ESTNewsCatabasis Pharmaceuticals: Transformation Through Quellis Biosciences AcquisitionN/A
2021-03-16 20:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $5.Neutral
2021-03-13 23:18 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 03:19 ESTEarnings EstimateAn EPS average of -$0.05 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-12 03:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $24 to $14.5.Neutral
2021-03-12 03:19 ESTEarnings EstimateAn EPS average of -$0.39 is estimated for the 2022 year.Buy
2021-03-12 01:01 ESTNewsCatabasis Pharmaceuticals EPS misses by $0.20N/A
2021-02-17 18:38 ESTNewsCan't Get My Head Around Catabasis PharmaceuticalsN/A
2021-01-29 15:21 ESTNewsCatabasis Pharma shares surge after Quellis Biosciences dealN/A
2020-12-13 03:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 11:31 ESTAnalyst RatingThe Analyst Target Price has increased from $12.57 to $24.Buy
2020-11-15 11:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 03:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 11:30 ESTEarnings EstimateAn EPS average of -$0.30 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-12 19:32 ESTNewsCatabasis Pharmaceuticals reports Q3 resultsN/A
2020-11-03 11:18 ESTAnalyst RatingThe Analyst Target Price has decreased from $33 to $12.57.Neutral
2020-11-01 17:26 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 13:25 ESTNewsCatabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of BiopharmaN/A
2020-10-27 16:38 ESTNewsCatabasis -64% after halting development of edasalonexentN/A
2020-10-16 16:23 ESTNewsCatabasis Pharmaceuticals: Accumulating Ahead Of Edasalonexent's Top-Line ResultsN/A
2020-10-03 00:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $37.5 to $33.Neutral
2020-09-24 00:23 ESTFinancialsCompany financials have been released.Neutral
2020-09-21 17:00 ESTNewsCatabasis names Noah Clauser as CFON/A
2020-09-19 08:26 ESTFinancialsCompany financials have been released.Neutral
2020-09-16 15:17 ESTNewsCatabasis Pharmaceuticals Inc (CATB) Investor Presentation - SlideshowN/A
2020-08-26 09:37 ESTNewsDyne Therapeutics on deck for IPON/A
2020-08-13 04:19 ESTFinancialsCompany financials have been released.Neutral
2020-08-11 09:56 ESTNewsCatabasis Pharmaceuticals EPS misses by $0.07N/A
2020-07-31 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-10 08:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 08:16 ESTFinancialsCompany financials have been released.Neutral
2020-06-29 19:24 ESTNewsCatabasis joins Russell 3000 indexN/A
2020-06-13 15:14 ESTNewsCatabasis Pharmaceuticals names Ben Harshbarger as Senior VP, General CounselN/A
2020-06-02 08:18 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on September 30, 2020.Buy
2020-05-31 16:48 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 20:15 ESTFinancialsCompany financials have been released.Neutral
2020-05-13 01:50 ESTNewsCatabasis Pharmaceuticals EPS misses by $0.09N/A
2020-05-03 08:23 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 06:43 ESTNewsKey events next week - healthcareN/A
2020-04-11 06:28 ESTNewsCatabasis Pharmaceuticals EPS beats by $0.07N/A
2020-04-07 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-03-25 04:08 ESTNewsCatabasis: Worth A Look Ahead Of Phase III DataN/A
2020-03-13 00:18 ESTFinancialsCompany financials have been released.Neutral
2020-03-11 12:08 ESTNewsCatabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call TranscriptN/A
2020-03-11 04:17 ESTAnalyst RatingThe Analyst Target Price has decreased from $39 to $37.5.Neutral
2020-03-11 04:17 ESTEarnings EstimateAn EPS average of -$0.12 is estimated for the 2021 year.Buy

About Catabasis Pharmaceuticals, Inc (CATB):

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

CATB Quotes by TradingView

See Advanced Chart

General

  • Name Catabasis Pharmaceuticals, Inc
  • Symbol CATB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 20
  • Last Split Factor1:10
  • Last Split Date2018-12-31
  • Fiscal Year EndDecember
  • IPO Date2015-06-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.catabasis.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.06
  • Enterprise Value EBITDA 0.12
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.66
  • Next Year EPS Estimate -$0.64
  • Return on Assets -52%
  • Return on Equity -98%
  • Earnings Per Share -$2.81
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 78.68 million
  • EBITDA -24826000
  • Analyst Target Price $5
  • Book Value Per Share $2.03
View More

Share Statistics

  • Shares Outstanding 23.42 million
  • Shares Float 20.37 million
  • % Held by Insiders 13%
  • % Held by Institutions 40.64%
  • Shares Short 2.58 million
  • Shares Short Prior Month 2.39 million
  • Short Ratio 0.17
  • Short % of Float 13%
  • Short % of Shares Outstanding 11%
View More

Technicals

  • Beta 1.88
  • 52 Week High $8.59
  • 52 Week Low $1.25
  • 50 Day Moving Average 3.25
  • 200 Day Moving Average 3.55
View More

Dividends

  • Dividend Date 2018-12-31
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Catabasis Pharmaceuticals, Inc (CATB) Dividend Calendar:

CATB's last dividend payment was made to shareholders on December 31, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Catabasis Pharmaceuticals, Inc (CATB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.44-$0.34-29.41%
2020-09-302020-11-12$N/A-$0.56-$0.51-9.8%
2020-06-302020-08-10$N/A-$0.53-$0.46-16.48%
2020-03-312020-05-12$N/A-$0.50-$0.41-21.95%
2019-12-312020-03-10$N/A-$0.55-$0.6210.57%
2019-09-302019-11-07$N/A-$0.56-$0.6411.99%
2019-06-302019-08-08$N/A-$0.62-$0.61-2.21%
2019-03-312019-05-14$N/A-$0.62-$0.7010.79%
2018-12-312019-03-14$N/A-$0.85-$0.905.87%
2018-09-302018-11-13$N/A-$0.80-$1.3540.66%
2018-06-302018-08-09$N/A-$2.00-$2.6524.53%
2018-03-312018-05-10$N/A-$2.90-$2.25-28.89%
2017-12-312018-03-15$250000-$2.40-$3.0521.31%
2017-09-302017-11-09$250000-$3.10-$3.275.1%
2017-06-302017-08-10$N/A-$3.20-$3.9017.95%
2017-03-312017-05-11$N/A-$4.10-$4.539.56%
2016-12-312017-03-16$N/A-$4.70-$4.883.59%
2016-09-302016-11-10$N/A-$5.40-$6.4716.5%
2016-06-302016-08-11$N/A-$6.10-$6.404.69%
2016-03-312016-05-12$N/A-$6.10-$6.404.69%
2015-12-312016-03-02$N/A-$6.30-$7.1311.68%
2015-09-302015-11-12$N/A-$0.55-$0.6414.06%
2015-06-302015-08-13$N/A-$8.07-$0.71-1036.62%

Catabasis Pharmaceuticals, Inc (CATB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Catabasis Pharmaceuticals, Inc (CATB) Chart:

Catabasis Pharmaceuticals, Inc (CATB) News:

Below you will find a list of latest news for Catabasis Pharmaceuticals, Inc (CATB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Catabasis Pharmaceuticals, Inc (CATB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Catabasis Pharmaceuticals, Inc (CATB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072749/0001104659-20-072749-index.htm
2018-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1454789/000000000018017932/0000000000-18-017932-index.htm
2019-05-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1454789/000000000019008747/0000000000-19-008747-index.htm
2018-06-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000090266418002661/0000902664-18-002661-index.htm
2019-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000090266419000273/0000902664-19-000273-index.htm
2018-07-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000091957418004481/0000919574-18-004481-index.htm
2019-02-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000091957419001878/0000919574-19-001878-index.htm
2018-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000093583618000365/0000935836-18-000365-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000093583619000104/0000935836-19-000104-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000093583620000110/0000935836-20-000110-index.htm
2018-06-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1454789/000104746918004419/0001047469-18-004419-index.htm
2018-06-15S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1454789/000104746918004492/0001047469-18-004492-index.htm
2018-06-18S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1454789/000104746918004538/0001047469-18-004538-index.htm
2018-06-20S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1454789/000104746918004590/0001047469-18-004590-index.htm
2018-06-20424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1454789/000104746918004625/0001047469-18-004625-index.htm
2018-10-12PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1454789/000104746918006698/0001047469-18-006698-index.htm
2018-10-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1454789/000104746918006826/0001047469-18-006826-index.htm
2018-11-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000104746918007191/0001047469-18-007191-index.htm
2019-02-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000104746919000358/0001047469-19-000358-index.htm
2019-02-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000104746919000374/0001047469-19-000374-index.htm
2019-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1454789/000104746919001212/0001047469-19-001212-index.htm
2019-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1454789/000104746919002458/0001047469-19-002458-index.htm
2019-05-14POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1454789/000104746919003078/0001047469-19-003078-index.htm
2019-05-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1454789/000104746919003079/0001047469-19-003079-index.htm
2019-05-22S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1454789/000104746919003254/0001047469-19-003254-index.htm
2019-05-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1454789/000104746919003278/0001047469-19-003278-index.htm
2019-05-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1454789/000104746919003279/0001047469-19-003279-index.htm
2019-05-23424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1454789/000104746919003280/0001047469-19-003280-index.htm
2020-01-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000104746920000582/0001047469-20-000582-index.htm
2020-01-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000104746920000612/0001047469-20-000612-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1454789/000104746920001338/0001047469-20-001338-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1454789/000104746920002643/0001047469-20-002643-index.htm
2018-06-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1454789/000110465918040968/0001104659-18-040968-index.htm
2018-06-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1454789/000110465918040969/0001104659-18-040969-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465918041160/0001104659-18-041160-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465918050776/0001104659-18-050776-index.htm
2018-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465918062289/0001104659-18-062289-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465918067718/0001104659-18-067718-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465918067755/0001104659-18-067755-index.htm
2018-11-13424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1454789/000110465918067758/0001104659-18-067758-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465918072953/0001104659-18-072953-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465918075355/0001104659-18-075355-index.htm
2018-12-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1454789/000110465918075356/0001104659-18-075356-index.htm
2019-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919001374/0001104659-19-001374-index.htm
2019-02-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000110465919005823/0001104659-19-005823-index.htm
2019-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919006087/0001104659-19-006087-index.htm
2019-02-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1454789/000110465919006093/0001104659-19-006093-index.htm
2019-02-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1454789/000110465919007909/0001104659-19-007909-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919008694/0001104659-19-008694-index.htm
2019-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1454789/000110465919022873/0001104659-19-022873-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465919029116/0001104659-19-029116-index.htm
2019-05-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1454789/000110465919030801/0001104659-19-030801-index.htm
2019-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919034023/0001104659-19-034023-index.htm
2019-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919042921/0001104659-19-042921-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465919044710/0001104659-19-044710-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919050067/0001104659-19-050067-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919051019/0001104659-19-051019-index.htm
2019-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919054384/0001104659-19-054384-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465919060826/0001104659-19-060826-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465919074075/0001104659-19-074075-index.htm
2019-12-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465919074077/0001104659-19-074077-index.htm
2020-01-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465920008669/0001104659-20-008669-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1454789/000110465920052392/0001104659-20-052392-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465920060145/0001104659-20-060145-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072654/0001104659-20-072654-index.htm
2020-06-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072655/0001104659-20-072655-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072726/0001104659-20-072726-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072733/0001104659-20-072733-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072734/0001104659-20-072734-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072735/0001104659-20-072735-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072736/0001104659-20-072736-index.htm
2020-06-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072740/0001104659-20-072740-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072742/0001104659-20-072742-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920072749/0001104659-20-072749-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1454789/000110465920092697/0001104659-20-092697-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465920106764/0001104659-20-106764-index.htm
2020-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000110465920106765/0001104659-20-106765-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1454789/000110465920118204/0001104659-20-118204-index.htm
2018-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911018011280/0001179110-18-011280-index.htm
2018-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911018011282/0001179110-18-011282-index.htm
2018-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911018011283/0001179110-18-011283-index.htm
2018-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911018011284/0001179110-18-011284-index.htm
2019-01-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019000342/0001179110-19-000342-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019000343/0001179110-19-000343-index.htm
2019-01-044/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019000404/0001179110-19-000404-index.htm
2019-02-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001937/0001179110-19-001937-index.htm
2019-02-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001938/0001179110-19-001938-index.htm
2019-02-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001939/0001179110-19-001939-index.htm
2019-02-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001940/0001179110-19-001940-index.htm
2019-02-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001941/0001179110-19-001941-index.htm
2019-02-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001942/0001179110-19-001942-index.htm
2019-02-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019001943/0001179110-19-001943-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019007182/0001179110-19-007182-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019007183/0001179110-19-007183-index.htm
2019-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019007184/0001179110-19-007184-index.htm
2019-07-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019008892/0001179110-19-008892-index.htm
2019-07-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019008893/0001179110-19-008893-index.htm
2019-09-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019010492/0001179110-19-010492-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911019010493/0001179110-19-010493-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911020001597/0001179110-20-001597-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911020001598/0001179110-20-001598-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911020001600/0001179110-20-001600-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911020001601/0001179110-20-001601-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1454789/000117911020001613/0001179110-20-001613-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000119312519038264/0001193125-19-038264-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000119312520029762/0001193125-20-029762-index.htm
2020-02-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000138713120001217/0001387131-20-001217-index.htm
2018-07-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000162363218000855/0001623632-18-000855-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000162363219000243/0001623632-19-000243-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1454789/000162363220000259/0001623632-20-000259-index.htm
2018-06-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1454789/999999999518001544/9999999995-18-001544-index.htm
2019-05-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1454789/999999999519001170/9999999995-19-001170-index.htm
2019-05-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1454789/999999999519001201/9999999995-19-001201-index.htm